Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network

Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations fo...

Full description

Saved in:
Bibliographic Details
Published in:Swiss medical weekly Vol. 155; no. 7; p. 4219
Main Authors: Rieger, Max J., Flammer, Andreas J., Gerull, Sabine, Pabst, Thomas, Auner, Holger W., Samii, Kaveh, Hitz, Felicitas, Mey, Ulrich, Ballova, Veronika, Battegay, Raphael, Melli, Giorgia, Benz, Dominik, Yakupoglu, Yakup, Gräni, Christoph, Schläger, Regina, Hugelshofer, Sarah, Studer, Annina, Oechslin, Luca, Bakula, Adam, Suter, Thomas M., Leo-Stickelberger, Julia, Averiamo, Manuela, Fehr, Thomas, Jung, Hans H., Laptseva, Natallia, Manka, Robert, Rüfer, Axel, Schmidt, Adrian, Seeger, Harald, Müllhaupt, Beat, Stämpfli, Simon F., De Ramon Ortiz, Carmen, Théaudin, Marie, Gerber, Bernhard, Schwotzer, Rahel
Format: Journal Article
Language:English
Published: Switzerland SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 17.07.2025
Subjects:
Antibodies, Monoclonal - therapeutic use
Bortezomib - therapeutic use
Cyclophosphamide - therapeutic use
Dexamethasone - therapeutic use
Humans
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunoglobulin Light-chain Amyloidosis - therapy
Practice Guidelines as Topic
Switzerland
Switzerland
ISSN:1424-3997, 1424-3997
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous “therapeutic recommendations” while the previous “diagnostic recommendations” remain valid.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1424-3997
1424-3997
DOI:10.57187/s.4219